During a live event, James W. Smithy, MD, MHS, and other oncologists discussed the tolerability of different immune ...

Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced its novel B7-H3-targeting ADC (R&D code: 7MW3711) has been approved by the NMPA to enter Phase Ib/II ...

First-ever positive profit, entering a new era of growth and global innovation SAN FRANSISCO and SUZHOU, China, March 26, 2025 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: ...

First-ever positive profit, entering a new era of growth and global innovation ...

NEU-411 is a brain-penetrant, potent and selective inhibitor of LRRK2 for the treatment of Parkinson’s disease (PD). Initial findings will be presented in a poster titled, “A Phase 1 Study of ...

Retrospective Analysis of BRCA-Altered Uterine Sarcoma Treated With Poly(ADP-ribose) Polymerase Inhibitors ... PD-L1–positive tumor cells divided by the total number of PD-L1–positive and ...

While they help prevent autoimmunity, many cancers exploit this pathway to evade immune detection. PD-1 and PD-L1 inhibitors are immunotherapies designed to block this mechanism, allowing the immune ...

“Camrelizumab, a humanized high-affinity anti–PD-1 immunoglobulin G4-κ monoclonal antibody, has significantly improved median progression-free survival from 6.9 months to 9.7 months when combined with ...

Department of Radiology and Imaging Sciences, Emory University, Atlanta, Georgia 30322, United States Department of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia ...

- Trials are designed to demonstrate whether the addition of Actimab-A to either KEYTRUDA ® or OPDIVO ® can result in improved patient outcomes - MDSCs – Myeloid Derived Suppressor Cells in ...

This expansion will evaluate the combination of Decoy20 with BeiGene’s PD-1 checkpoint inhibitor, tislelizumab, with a focus on safety, dose optimization, and early signs of anti-tumor activity.